Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) — Tiziana Life Sciences Ltd. (Nasdaq:TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 20,145 common shares priced between $0.66 per share.
Related news for (TLSA)
- MoBot’s Stock Market Highlights – 07/30/25 04:00 PM
- 24/7 Market News Snapshot 23 May, 2025 – Tiziana Life Sciences Ltd. Common Shares (NASDAQ:TLSA)
- Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease
- Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer’s Patient Treated with Intranasal Foralumab
- Breaking News: MoBot’s Latest Update as of 05/06/25 02:00 PM